Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Age over 18 years~2. The ability to provide informed consent for enrollment in the study~3. Diagnosis of conjunctival nevus (Group 1 only)~4. Diagnosis of racial melanosis (Group 2 only)~5. Diagnosis or suspicion of primary acquired melanosis (PAM), scheduled for biopsy (Group 3 only)~6. Diagnosis of possible MM scheduled for biopsy (Group 4 only)~7. Confirmed diagnosis of MM based upon clinical and histopathological findings, and have already undergone resection(Group 4 only)~8. Confirmed diagnosis of MM recurrence based upon clinical and histopathological findings(Group 4 only)~9. Clear cornea (Group 5 only)~10. No conjunctival lesions or recent conjunctival diseases(Group 5 only)~11. No recent chemotherapy or radiotherapy(Group 5 only)~Exclusion criteria:~1. History of previous ocular surgery within last 3 months~2. History of inflammatory eye diseases within last 3 months~3. Current or history of glaucoma disease and on glaucoma medication~4. Contact lens use within last 3 months~5. Physical inability to cooperate for confocal microscopy~6. Prior history of infectious keratitis within 3 months~7. Suspicion for PAM or malignant melanoma (MM)(Groups 1,2,3)~8. History of PAM or MM(Groups 1,2,3)~9. Histopathology not confirmatory for MM (group 4 only)~10. History of other ocular carcinoma or any recent ocular topical chemotherapy or radiotherapy (Group 5 only)~11. History of cancer elsewhere in the body which is currently under systemic chemotherapy (group 5 only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nevus (Type: None): None
- Racial Melanosis (Type: None): None
- Primary Acquired Melanosis (Type: None): None
- Malignant Melanoma (Type: None): None
- Normal (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).